Cilostazol inhibits high glucose- and angiotensin II-induced type 1 plasminogen activator inhibitor expression in artery wall and neointimal region after vascular injury

Atherosclerosis

Volumn 207, Issue 2, 2009, Pages 391-398

  Lee, Kyeong Min ^a   Lee, Hyo Jeong ^a   Kim, Mi Kyung ^b   Kim, Hye Soon ^b   Jung, Gwon Soo ^b   Hur, Seung Ho ^b   Kim, Hyoung Tae ^b   Cho, Won Hyun ^b   Kim, Jung Guk ^a   Kim, Bo Wan ^a   Lim, Jeong Ok ^a   Choi, Hueng Sik ^c   Lee, Ki Up ^d   Park, Keun Gyu ^b   Lee, In Kyu ^a  

^a Kyungpook National University School of Medicine   (South Korea)

^b Keimyung University School of Medicine   (South Korea)

^c Chonnam National University   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

Author keywords

Angiotensin II; Cilostazol; Diabetes; PAI 1; Vascular smooth muscle cells

Indexed keywords

ANGIOTENSIN II; CILOSTAZOL; GLUCOSE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHODIESTERASE III INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; SMAD3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA;

ANGIOPLASTY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIANGIOGENIC ACTIVITY; ARTERY INTIMA PROLIFERATION; ARTERY WALL; ARTICLE; BALLOON; BLOOD VESSEL INJURY; CONTROLLED STUDY; DIABETES MELLITUS; DOWN REGULATION; GENE ACTIVITY; GENETIC TRANSCRIPTION; IN VITRO STUDY; IN VIVO STUDY; INTIMA; MALE; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RAT; RESTENOSIS; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; STENT; STENT THROMBOSIS; VASCULAR SMOOTH MUSCLE; VASCULAR TISSUE;

ANGIOPLASTY, BALLOON; ANGIOTENSIN II; ANIMALS; BINDING SITES; BLOOD GLUCOSE; CAROTID ARTERIES; CAROTID ARTERY INJURIES; CELL PROLIFERATION; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYTIC AGENTS; HYPERPLASIA; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MUSCLE, SMOOTH, VASCULAR; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHODIESTERASE INHIBITORS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROMOTER REGIONS, GENETIC; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; TETRAZOLES; TRANSCRIPTIONAL ACTIVATION; TRANSFORMING GROWTH FACTOR BETA; TUNICA INTIMA;

EID: 70450227453     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.06.016     Document Type: Article

References (26)

1. Krolewski A.S., Warram J.H., Valsania P., et al. Evolving natural history of coronary artery disease in diabetes mellitus. Am J Med 90 (1991) 56S-61S
2. Schneiderman J., Sawdey M.S., Keeton M.R., et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 89 (1992) 6998-7002
3. Hamsten A., de Faire U., Walldius G., et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 2 (1987) 3-9
4. Huber K., Jörg M., Probst P., et al. A decrease in plasminogen activator inhibitor-1 activity after successful percutaneous transluminal coronary angioplasty is associated with a significantly reduced risk for coronary restenosis. Thromb Haemost 67 (1992) 209-213
5. Chen Y.Q., Su M., Walia R.R., et al. Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells. J Biol Chem 273 (1998) 8225-8231
6. Otsuka G., Agah R., Frutkin A.D., et al. Transforming growth factor beta 1 induces neointima formation through plasminogen activator inhibitor-1-dependent pathways. Arterioscler Thromb Vasc Biol 26 (2006) 737-743
7. van Leeuwen R.T., Kol A., Andreotti F., et al. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation 90 (1994) 362-368
8. DeYoung M.B., Tom C., and Dichek D.A. Plasminogen activator inhibitor type 1 increases neointima formation in balloon-injured rat carotid arteries. Circulation 104 (2001) 1972-2071
9. Morice M.C., Serruys P.W., Sousa J.E., et al. Randomized study with the sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus eluting stent with standard stent for coronary revascularization. N Engl J Med 346 (2002) 1773-1780
10. Virmani R., Guagliumi G., Farb A., Musumeci G., et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent. Should we be cautious?. Circulation 109 (2004) 701-705
11. McFadden E.P., Stabile E., Regar E., et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364 (2004) 1519-1521
12. Katsaros K.M., Speidl W.S., Kastl S.P., et al. Plasminogen activator inhibitor-1 predicts coronary in-stent restenosis of drug-eluting stents. J Thromb Haemost 6 (2008) 508-513
13. Muldowney III J.A., Stringham J.R., Levy S.E., et al. Antiproliferative agents alter vascular plasminogen activator inhibitor-1 expression: a potential prothrombotic mechanism of drug eluting stents. Arterioscler Thromb Vasc Biol 27 (2007) 400-406
14. Dawson D.L., Cutler B.S., Meissner M.H., and Strandness Jr. D.E. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 98 (1998) 678-686
15. Douglas Jr. J.S., Holmes Jr. D.R., Kereiakes D.J., et al. Coronary stent restenosis in patients treated with cilostazol. Circulation 112 (2005) 2826-2832
16. Ahn Y., Jeong M.H., Jeong J.W., et al. Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients-clilostazol for diabetic patients in drug-eluting stent (CIDES) trial. Circ J 72 (2008) 35-39
17. Kim M.J., Park K.G., Lee K.M., et al. Cilostazol inhibits vascular smooth muscle cell growth by downregulation of the transcription factor E2F. Hypertension 45 (2005) 552-556
18. Ahn J.D., Morishita R., Kaneda Y., et al. Novel E2F decoy oligodeoxynucleotides inhibit in vitro vascular smooth muscle cell proliferation and in vivo neointimal hyperplasia. Gene Ther 9 (2002) 1682-1692
19. Ahn J.D., Morishita R., Kaneda Y., et al. Inhibitory effects of novel AP-1 decoy oligodeoxynucleotides on vascular smooth muscle cell proliferation in vitro and neointimal formation in vivo. Circ Res 90 (2002) 1325-1332
20. Park K.G., Lee K.M., Chang Y.C., et al. The ascochlorin derivative, AS-6, inhibits TNF-alpha induced adhesion molecule and chemokine expression in rat vascular smooth muscle cells. Life Sci 80 (2006) 120-126
21. Saitoh S., Saito T., Otake A., Owada T., Mitsugi M., Hashimoto H., and Maruyama Y. Cilostazol, a novel cyclic AMP phosphodiesterase inhibitor, prevents reocclusion after coronary arterial thrombolysis with recombinant tissue-type plasminogen activator. Arterioscler Thromb 13 (1993) 563-570
22. Binder B.R., Christ G., Gruber F., et al. Plasminogen activator inhibitor 1: physiological and pathophysiological roles. News Physiol Sci 17 (2002) 56-61
23. Javelaud D., and Mauviel A. Mammalian transforming growth factor-betas: Smad signaling and physio-pathological roles. Int J Biochem Cell Biol 36 (2004) 1161-1165
24. Suzuki M., Akimoto K., and Hattori Y. Glucose upregulates plasminogen activator inhibitor-1 gene expression in vascular smooth muscle cells. Life Sci 72 (2002) 59-66
25. Ahn J.D., Morishita R., Kaneda Y., et al. Transcription factor decoy for activator protein-1 (AP-1) inhibits high glucose- and angiotensin II-induced type 1 plasminogen activator inhibitor (PAI-1) gene expression in cultured human vascular smooth muscle cells. Diabetologia 44 (2001) 713-720
26. Vayalil P.K., Iles K.E., Choi J., et al. Glutathione suppresses TGF-beta-induced PAI-1 expression by inhibiting p38 and JNK MAPK and the binding of AP-1, SP-1, and Smad to the PAI-1 promoter. Am J Physiol Lung Cell Mol Physiol 293 (2007) 1281-1292